Elutia Inc Class A (ELUT)

Elutia's stock price has declined significantly, from $4.12 per share on November 22, 2024, to $0.59 as of November 21, 2025. In September 2025, Elutia sold its BioEnvelope business to Boston Scientific for $88 million, with the sale closing on October 1, 2025. The company reported its third-quarter 2025 financial results on November 6, 2025, with EPS exceeding expectations but revenues lagging. On November 12, 2025, Nasdaq granted Elutia a 180-day compliance period, indicating a delisting risk. In November 2025, there were reports of insider buying, and Elutia's price target was decreased by 12.50% to $3.57.

Information regarding specific demand seasonality for Elutia, Inc.'s products and services was not found in the provided search results.

Elutia, Inc. is a commercial-stage biotechnology company focused on developing and commercializing drug-eluting biologics products within the Healthcare sector. The company's proprietary polymeric nitric oxide platform aims to improve compatibility between medical devices and patients through controlled nitric oxide release. Elutia's product portfolio includes Device Protection, Women's Health, and Cardiovascular segments. The Device Protection segment includes products like CanGaroo and EluPro (sold to Boston Scientific). The Women's Health segment includes SimpliDerm and NXT-41x. The Cardiovascular segment offers products like ProxiCor, Tyke, and VasCure.

Elutia, Inc. primarily develops and commercializes its products in the United States, serving hospitals and healthcare facilities through various sales channels. The company is headquartered in Gaithersburg, Maryland, with an address also listed in Silver Spring, Maryland.

Elutia's brand reputation is mixed, with strong revenue growth in its BioEnvelope product line and improved gross margin. The sale of its BioEnvelope business to Boston Scientific was a validation of its technology. Analysts have given Elutia a consensus rating of "Hold" or "Buy." However, the company received a Nasdaq delisting risk notice, and some product lines experienced revenue declines. Analysts have noted a slower-than-anticipated sales trajectory and reliance on a limited number of key products as risks.

As of November 2025, Elutia Inc. has 46 institutional owners and shareholders holding a total of 18,415,732 shares, representing 74.03% of the stock. Major institutional owners include Nantahala Capital Management, LLC, AIGH Capital Management LLC, and Silverarc Capital Management, Llc. Insiders hold 27.60% of the company's stock, and have bought more company stock than they have sold in the past three months.